Home/Filings/4/0000899243-23-000629
4//SEC Filing

Seymour Albert 4

Accession 0000899243-23-000629

CIK 0001661998other

Filed

Jan 3, 7:00 PM ET

Accepted

Jan 4, 4:35 PM ET

Size

11.4 KB

Accession

0000899243-23-000629

Insider Transaction Report

Form 4
Period: 2023-01-01
Seymour Albert
Chief Scientific Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2023-01-01+4,290139,856 total
  • Exercise/Conversion

    Restricted Stock Units

    2023-01-014,2904,420 total
    Common Stock (4,290 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2023-01-016,93014,070 total
    Common Stock (6,930 underlying)
  • Exercise/Conversion

    Common Stock

    2023-01-01+6,930146,786 total
Footnotes (4)
  • [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer common stock.
  • [F2]Includes 3,920 shares acquired under Issuer's Employee Stock Purchase Plan on August 31, 2022.
  • [F3]The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2021 so that such RSUs will become fully vested on January 1, 2024. The RSUs do not have an expiration date.
  • [F4]The RSUs have vested and settled or will vest and settle, as applicable, as to approximately one third of the RSUs on each of the first three anniversaries of January 1, 2022 so that such RSUs will become fully vested on January 1, 2025. The RSUs do not have an expiration date.

Issuer

Homology Medicines, Inc.

CIK 0001661998

Entity typeother

Related Parties

1
  • filerCIK 0001735324

Filing Metadata

Form type
4
Filed
Jan 3, 7:00 PM ET
Accepted
Jan 4, 4:35 PM ET
Size
11.4 KB